Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02222207 · ClinicalTrials.gov registry record · Phase 2
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT02222207 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 52 participants.
The verdict
NCT02222207, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objectives: The study will also evaluate the safety and tolerability of the regorafenib eye drops. Part B (Phase IIb): Primary objectives: The study part B is designed to investigate: * how often the regorafenib eye drops need to be given per day * whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objectives: The study will also evaluate how the different dosings of regorafenib eye drops affect patients vision, the safety and the tolerability.
Interventions
- DRUG Placebo
- DRUG Ranibizumab
- DRUG Regorafenib, ophthalmic oily suspension (BAY73-4506)
- PROCEDURE Sham IVT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02222207
The ClinicalTrials.gov registry entry for NCT02222207 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02222207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02222207 about?
NCT02222207 is a clinical study titled "Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration". Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4 weeks and 12 weeks after inclusion into this study. Secondary objecti...
What is the current status of trial NCT02222207?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-10. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02222207?
The interventions under investigation include: Placebo (DRUG), Ranibizumab (DRUG), Regorafenib, ophthalmic oily suspension (BAY73-4506) (DRUG), Sham IVT (PROCEDURE).
Who is sponsoring clinical trial NCT02222207?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.